Table 2 Demographic and clinical characteristics of individuals who were seronegative and individuals who were seropositive (as per the ≥0.8 U/ml cut-off for Spike-antibody level) at ≥28 days after receiving Dose 1, with percentage estimates and 95% confidence intervals for seropositivity and seronegativity rates
ChAdOx1 Dose 1 (≥28 days) | BNT162b2 Dose 1 (≥28 days) | |||||||
|---|---|---|---|---|---|---|---|---|
Seronegative N = 166 | Seropositive N = 5364 | Seronegative N = 86 | Seropositive N = 2898 | |||||
n (%) | 95% CIa | n (%) | 95% CIa | n (%) | 95% CIa | n (%) | 95% CIa | |
Age group (years) | ||||||||
18–24 | 0 (0%) | 0.00%, 2.8% | 20 (0.4%) | 0.23%, 0.59% | 1 (1.2%) | 0.06%, 7.2% | 61 (2.1%) | 1.6%, 2.7% |
25–44 | 10 (6.0%) | 3.1%, 11% | 454 (8.5%) | 7.7%, 9.2% | 7 (8.1%) | 3.6%, 17% | 303 (10%) | 9.4%, 12% |
45–64 | 63 (38%) | 31%, 46% | 2545 (47%) | 46%, 49% | 17 (20%) | 12%, 30% | 736 (25%) | 24%, 27% |
65+ | 93 (56%) | 48%, 64% | 2345 (44%) | 42%, 45% | 61 (71%) | 60%, 80% | 1798 (62%) | 60%, 64% |
Sex | ||||||||
Male | 95 (57%) | 49%, 65% | 2268 (42%) | 41%, 44% | 47 (55%) | 44%, 65% | 1254 (43%) | 41%, 45% |
Female | 71 (43%) | 35%, 51% | 3096 (58%) | 56%, 59% | 39 (45%) | 35%, 56% | 1644 (57%) | 55%, 59% |
Ethnicity | ||||||||
White British | 153 (92%) | 87%, 96% | 4985 (93%) | 92%, 94% | 77 (90%) | 81%, 95% | 2646 (91%) | 90%, 92% |
Minority ethnic | 13 (7.8%) | 4.4%, 13% | 379 (7.1%) | 6.4%, 7.8% | 9 (10%) | 5.2%, 19% | 252 (8.7%) | 7.7%, 9.8% |
BMI | ||||||||
Normal | 62 (37%) | 30%, 45% | 2064 (38%) | 37%, 40% | 35 (41%) | 30%, 52% | 1096 (38%) | 36%, 40% |
Obese | 38 (23%) | 17%, 30% | 1043 (19%) | 18%, 21% | 22 (26%) | 17%, 36% | 535 (18%) | 17%, 20% |
Overweight | 53 (32%) | 25%, 40% | 1801 (34%) | 32%, 35% | 24 (28%) | 19%, 39% | 1024 (35%) | 34%, 37% |
Underweight | 0 (0%) | 0.00%, 2.8% | 68 (1.3%) | 1.0%, 1.6% | 2 (2.3%) | 0.40%, 8.9% | 32 (1.1%) | 0.77%, 1.6% |
Missing | 13 (7.8%) | 4.4%, 13% | 388 (7.2%) | 6.6%, 8.0% | 3 (3.5%) | 0.91%, 11% | 211 (7.3%) | 6.4%, 8.3% |
Clinical vulnerability | ||||||||
Not clinically vulnerable | 57 (34%) | 27%, 42% | 3110 (58%) | 57%, 59% | 21 (24%) | 16%, 35% | 1488 (51%) | 50%, 53% |
Clinically vulnerable | 52 (31%) | 24%, 39% | 1583 (30%) | 28%, 31% | 23 (27%) | 18%, 38% | 961 (33%) | 31%, 35% |
Clinically extremely vulnerable | 57 (34%) | 27%, 42% | 671 (13%) | 12%, 13% | 42 (49%) | 38%, 60% | 449 (15%) | 14%, 17% |
Solid organ cancer (non-Haem) | 19 (11%) | 7.2%, 18% | 444 (8.3%) | 7.6%, 9.1% | 13 (15%) | 8.6%, 25% | 290 (10%) | 9.0%, 11% |
Haematological cancer | 15 (9.0%) | 5.3%, 15% | 38 (0.7%) | 0.51%, 1.0% | 7 (8.1%) | 3.6%, 17% | 24 (0.8%) | 0.54%, 1.2% |
Haematological non-malignant | 4 (2.4%) | 0.77%, 6.4% | 36 (0.7%) | 0.48%, 0.94% | 4 (4.7%) | 1.5%, 12% | 17 (0.6%) | 0.35%, 1.0% |
Asthma | 26 (16%) | 11%, 22% | 905 (17%) | 16%, 18% | 7 (8.1%) | 3.6%, 17% | 495 (17%) | 16%, 19% |
COPD | 11 (6.6%) | 3.5%, 12% | 160 (3.0%) | 2.6%, 3.5% | 8 (9.3%) | 4.4%, 18% | 114 (3.9%) | 3.3%, 4.7% |
Severe respiratory disease | 7 (4.2%) | 1.9%, 8.8% | 290 (5.4%) | 4.8%, 6.1% | 4 (4.7%) | 1.5%, 12% | 145 (5.0%) | 4.3%, 5.9% |
Ischaemic heart disease | 13 (7.8%) | 4.4%, 13% | 238 (4.4%) | 3.9%, 5.0% | 10 (12%) | 6.0%, 21% | 185 (6.4%) | 5.5%, 7.4% |
Hypertension | 65 (39%) | 32%, 47% | 1406 (26%) | 25%, 27% | 28 (33%) | 23%, 44% | 956 (33%) | 31%, 35% |
Heart failure | 5 (3.0%) | 1.1%, 7.3% | 21 (0.4%) | 0.25%, 0.61% | 4 (4.7%) | 1.5%, 12% | 20 (0.7%) | 0.43%, 1.1% |
Chronic viral infection | 1 (0.6%) | 0.03%, 3.8% | 29 (0.5%) | 0.37%, 0.79% | 0 (0%) | 0.00%, 5.3% | 9 (0.3%) | 0.15%, 0.61% |
Type 1 DM | 2 (1.2%) | 0.21%, 4.7% | 27 (0.5%) | 0.34%, 0.74% | 2 (2.3%) | 0.40%, 8.9% | 15 (0.5%) | 0.30%, 0.87% |
Type 2 DM | 10 (6.0%) | 3.1%, 11% | 237 (4.4%) | 3.9%, 5.0% | 12 (14%) | 7.7%, 23% | 170 (5.9%) | 5.1%, 6.8% |
Stroke | 7 (4.2%) | 1.9%, 8.8% | 90 (1.7%) | 1.4%, 2.1% | 0 (0%) | 0.00%, 5.3% | 66 (2.3%) | 1.8%, 2.9% |
Neurological condition | 10 (6.0%) | 3.1%, 11% | 106 (2.0%) | 1.6%, 2.4% | 4 (4.7%) | 1.5%, 12% | 72 (2.5%) | 2.0%, 3.1% |
Mental ill-health | 2 (1.2%) | 0.21%, 4.7% | 82 (1.5%) | 1.2%, 1.9% | 4 (4.7%) | 1.5%, 12% | 39 (1.3%) | 1.0%, 1.9% |
Liver condition | 5 (3.0%) | 1.1%, 7.3% | 98 (1.8%) | 1.5%, 2.2% | 3 (3.5%) | 0.91%, 11% | 55 (1.9%) | 1.4%, 2.5% |
Inflammatory conditions | 24 (14%) | 9.7%, 21% | 325 (6.1%) | 5.4%, 6.7% | 14 (16%) | 9.5%, 26% | 232 (8.0%) | 7.1%, 9.1% |
Chronic kidney disease | 10 (6.0%) | 3.1%, 11% | 55 (1.0%) | 0.78%, 1.3% | 4 (4.7%) | 1.5%, 12% | 54 (1.9%) | 1.4%, 2.4% |
Immunosuppressive Drugs | ||||||||
Steroids (long course) | 16 (9.6%) | 5.8%, 15% | 72 (1.3%) | 1.1%, 1.7% | 7 (8.1%) | 3.6%, 17% | 36 (1.2%) | 0.88%, 1.7% |
DMARD | 23 (14%) | 9.2%, 20% | 85 (1.6%) | 1.3%, 2.0% | 15 (17%) | 10%, 27% | 69 (2.4%) | 1.9%, 3.0% |
MAB | 13 (7.8%) | 4.4%, 13% | 25 (0.5%) | 0.31%, 0.70% | 5 (5.8%) | 2.2%, 14% | 27 (0.9%) | 0.63%, 1.4% |
